专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08580292B2 Sustained release intraocular implants and methods for treating ocular vasculopathies 有权
公开(公告)号：US08580292B2
公开(公告)日：2013-11-12
申请号：US12024017
申请日：2008-01-31
申请人： Glenn T Huang , Brittany Jackson , James A. Burke , Ton Lin , Patrick M. Hughes , Larry A. Wheeler , Rosy Sheng Donn
发明人： Glenn T Huang , Brittany Jackson , James A. Burke , Ton Lin , Patrick M. Hughes , Larry A. Wheeler , Rosy Sheng Donn
IPC分类号： A61F2/00 , A61K31/498
CPC分类号： A61L31/148 , A61K9/0051 , A61K9/204 , A61K31/498 , A61K47/34 , A61L27/58 , A61L31/06 , A61L31/16 , A61L2300/436 , A61L2300/604 , C08L67/04 , Y02A50/401
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

2. 发明授权

US08506986B2 Sustained release intraocular implants and methods for treating ocular vasculopathies 有权
公开(公告)号：US08506986B2
公开(公告)日：2013-08-13
申请号：US12024014
申请日：2008-01-31
申请人： Glenn T Huang , Brittany Jackson , James A. Burke , Ton Lin , Patrick M. Hughes , Larry A. Wheeler , Rosy Sheng Donn
发明人： Glenn T Huang , Brittany Jackson , James A. Burke , Ton Lin , Patrick M. Hughes , Larry A. Wheeler , Rosy Sheng Donn
IPC分类号： A61K31/498 , A61K9/14
CPC分类号： A61L31/148 , A61K9/0051 , A61K9/204 , A61K31/498 , A61K47/34 , A61L27/58 , A61L31/06 , A61L31/16 , A61L2300/436 , A61L2300/604 , C08L67/04 , Y02A50/401
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.

3. 发明授权

US09161938B2 Sustained release intraocular implants and methods for treating ocular vasculopathies 有权
标题翻译：持续释放眼内植入物和治疗眼血管病变的方法
公开(公告)号：US09161938B2
公开(公告)日：2015-10-20
申请号：US12024010
申请日：2008-01-31
申请人： Glenn T. Huang , Brittany Jackson , James A. Burke , Ton Lin , Patrick M. Hughes , Larry A. Wheeler , Rosy Sheng Donn
发明人： Glenn T. Huang , Brittany Jackson , James A. Burke , Ton Lin , Patrick M. Hughes , Larry A. Wheeler , Rosy Sheng Donn
IPC分类号： A61K31/498 , A61K9/14 , A61L31/14 , C08L67/04 , A61K9/20 , A61L31/16 , A61L27/58 , A61K9/00
CPC分类号： A61L31/148 , A61K9/0051 , A61K9/204 , A61K31/498 , A61K47/34 , A61L27/58 , A61L31/06 , A61L31/16 , A61L2300/436 , A61L2300/604 , C08L67/04 , Y02A50/401
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others.
摘要翻译：生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。植入物可以放置在眼睛中以治疗一种或多种眼部病症，例如眼睛血管病变或青光眼等。

4. 发明授权

US08293741B2 Intraocular implants and methods for improving vision 有权
标题翻译：眼内植入物和改善视力的方法
公开(公告)号：US08293741B2
公开(公告)日：2012-10-23
申请号：US11119021
申请日：2005-04-29
申请人： James A. Burke , Patrick M. Hughes , Kai-Ming Zhang , Ton Lin , Glenn Huang , Brittany A. Jackson , Larry A. Wheeler , Rosy S. Donn
发明人： James A. Burke , Patrick M. Hughes , Kai-Ming Zhang , Ton Lin , Glenn Huang , Brittany A. Jackson , Larry A. Wheeler , Rosy S. Donn
IPC分类号： A61K31/495
CPC分类号： A61L31/148 , A61K9/0051 , A61K9/204 , A61K31/498 , A61K47/34 , A61L27/58 , A61L31/06 , A61L31/16 , A61L2300/436 , A61L2300/604 , C08L67/04 , Y02A50/401
摘要： Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants can be placed in an eye to treat one or more ocular conditions, such as an ocular vasculopathy or glaucoma, among others or to improve vision in a normal eye.
摘要翻译：生物相容性眼内植入物包括α-2肾上腺素能受体激动剂和与α-2肾上腺素能受体激动剂相关的聚合物，以促进α-2肾上腺素能受体激动剂延长一段时间的眼睛释放。 α-2肾上腺素能受体激动剂可以与可生物降解的聚合物基质例如两种可生物降解的聚合物的基质相关联。植入物可以放置在眼睛中以治疗一种或多种眼部病症，例如眼睛血管病变或青光眼等，或改善正常眼睛的视力。

5. 发明授权

US5756503A Methods for using (2-imidazolin-2-ylamino) Quinoxaline derivatives 失效
标题翻译：使用（2-咪唑啉-2-基氨基）喹喔啉衍生物的方法
公开(公告)号：US5756503A
公开(公告)日：1998-05-26
申请号：US636740
申请日：1996-04-19
申请人： James A. Burke , Michael E. Garst , Larry A. Wheeler
发明人： James A. Burke , Michael E. Garst , Larry A. Wheeler
IPC分类号： C07D401/12 , A61K31/495 , A61K31/498 , A61P1/12 , A61P1/14 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/02 , A61P13/02 , A61P13/12 , A61P15/00 , A61P23/00 , A61P23/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P27/16 , A61P29/00 , C07D403/12
CPC分类号： A61K31/498 , A61K31/495
摘要： A method of treating a mammal is disclosed comprising administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.
摘要翻译：公开了一种治疗哺乳动物的方法，其包括向哺乳动物施用有效量以在哺乳动物中提供期望的治疗效果，所述化合物选自具有下式的那些化合物及其药学上可接受的酸加成盐，以及其混合物，其中R 1和R 2各自选自含有1至4个碳原子的烷基和含有1至4个碳原子的烷氧基，2-咪唑啉-2-基氨基可以是5- 喹喔啉核的6-，7-或8-位，并且R3，R4和R5各自位于喹喔啉核的剩余的5-，6-，7-或8-位之一，并且独立地选自由Cl，Br，H组成的组和含有1至3个碳原子的烷基。当向哺乳动物施用时，这些化合物提供期望的治疗效果，例如减少外周疼痛。

6. 发明授权

US06329369B1 Methods of treating pain and other conditions 有权
标题翻译：治疗疼痛等症状的方法
公开(公告)号：US06329369B1
公开(公告)日：2001-12-11
申请号：US09679919
申请日：2000-10-05
申请人： Ken Chow , Daniel W. Gil , James A. Burke , Dale A. Harcourt , Michael E. Garst , Larry A. Wheeler , Stephen A. Munk
发明人： Ken Chow , Daniel W. Gil , James A. Burke , Dale A. Harcourt , Michael E. Garst , Larry A. Wheeler , Stephen A. Munk
IPC分类号： A61R314168
CPC分类号： C07D233/56 , C07D233/06 , C07D233/10 , C07D233/64 , C07D233/84 , C07D263/28 , C07D401/06 , C07D403/06 , C07D405/06 , C07D409/06 , C07D413/12 , C07D495/04 , Y10S514/816 , Y10S514/913
摘要： Methods of treating glaucoma or elevated pressure and other diseases with reduced side effects by treating a mammal in need thereof an agonist of the alpha 2B or alpha 2B/2C adrenergic receptor(s). Also described are compounds having such selective agonist activity.
摘要翻译：通过用有需要的哺乳动物治疗α2B或α2B / 2C肾上腺素能受体的激动剂来治疗青光眼或升高压力的其它疾病及其副作用降低的方法。还描述了具有这种选择性激动剂活性的化合物。

7. 发明授权

US5714486A Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives 失效
标题翻译：使用（2-咪唑啉-2-基氨基）喹喔啉衍生物的方法
公开(公告)号：US5714486A
公开(公告)日：1998-02-03
申请号：US695103
申请日：1996-08-07
申请人： James A. Burke , Michael E. Garst , Larry A. Wheeler
发明人： James A. Burke , Michael E. Garst , Larry A. Wheeler
IPC分类号： C07D401/12 , A61K31/495 , A61K31/498 , A61P1/12 , A61P1/14 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/02 , A61P13/02 , A61P13/12 , A61P15/00 , A61P23/00 , A61P23/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P27/16 , A61P29/00 , C07D403/12
CPC分类号： A61K31/498 , A61K31/495
摘要： A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 is each located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide anesthetization of the central nervous system.
摘要翻译：治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供选自下列化合物的化合物所需的治疗效果：具有下式的那些化合物及其药学上可接受的酸加成盐及其混合物其中R1和R2各自选自含有1至4个碳原子的烷基和含有1至4个碳原子的烷氧基，2-咪唑啉-2-基氨基可以是5-，6 - ，喹喔啉核的7-或8-位，并且R3，R4和R5各自位于喹喔啉核的剩余的5-，6-，7-或8-位之一，并且独立地选自由Cl，Br，H和含有1至3个碳原子的烷基组成。当向哺乳动物施用时，这些化合物提供中枢神经系统的麻醉。

8. 发明授权

US5703077A Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives 失效
标题翻译：使用（2-咪唑啉-2-基氨基）喹喔啉衍生物的方法
公开(公告)号：US5703077A
公开(公告)日：1997-12-30
申请号：US693745
申请日：1996-08-07
申请人： James A. Burke , Michael E. Garst , Larry A. Wheeler
发明人： James A. Burke , Michael E. Garst , Larry A. Wheeler
IPC分类号： C07D401/12 , A61K31/495 , A61K31/498 , A61P1/12 , A61P1/14 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/02 , A61P13/02 , A61P13/12 , A61P15/00 , A61P23/00 , A61P23/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P27/16 , A61P29/00 , C07D403/12
CPC分类号： A61K31/498 , A61K31/495
摘要： A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms wherein the desired therapeutic effect is an increase in renal fluid flow.
摘要翻译：治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供选自下列化合物的化合物所需的治疗效果：具有下式的那些化合物及其药学上可接受的酸加成盐及其混合物其中R1和R2各自选自含有1至4个碳原子的烷基和含有1至4个碳原子的烷氧基，2-咪唑啉-2-基氨基可以是5-，6 - ，喹喔啉核的7-位或8-位，R3，R4和R5各自位于喹喔啉核的剩余的5-，6-，7-或8-位之一，并且独立地选自由Cl，Br，H和含有1至3个碳原子的烷基组成，其中所需的治疗效果是肾液流动的增加。

9. 发明授权

US5587376A Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives 失效
标题翻译：使用（2-咪唑啉-2-基氨基）喹喔啉衍生物的方法
公开(公告)号：US5587376A
公开(公告)日：1996-12-24
申请号：US458949
申请日：1995-06-02
申请人： James A. Burke , Michael E. Garst , Larry A. Wheeler
发明人： James A. Burke , Michael E. Garst , Larry A. Wheeler
IPC分类号： C07D401/12 , A61K31/495 , A61K31/498 , A61P1/12 , A61P1/14 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/02 , A61P13/02 , A61P13/12 , A61P15/00 , A61P23/00 , A61P23/02 , A61P25/00 , A61P25/02 , A61P25/04 , A61P27/16 , A61P29/00 , C07D403/12
CPC分类号： A61K31/498 , A61K31/495
摘要： A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8- positions of the quinoxaline nucleus, and R.sub.3, R.sub.4 and R.sub.5 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as constriction of one or more blood vessels and decongestion of one or more nasal passages.
摘要翻译：治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供选自下列化合物的化合物所需的治疗效果：具有下式的那些化合物及其药学上可接受的酸加成盐及其混合物其中R1和R2各自选自含有1至4个碳原子的烷基和含有1至4个碳原子的烷氧基，2-咪唑啉-2-基氨基可以是5-，6 - ，喹喔啉核的7-位或8-位，R3，R4和R5各自位于喹喔啉核的剩余的5-，6-，7-或8-位之一，并且独立地选自由Cl，Br，H和含有1至3个碳原子的烷基组成。当向哺乳动物施用时，这些化合物提供所需的治疗效果，例如一个或多个血管的收缩和一个或多个鼻通道的减充血。

10. 发明授权

US06323204B1 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives 失效
标题翻译：使用（2-咪唑啉-2-基氨基）喹喔啉衍生物的方法
公开(公告)号：US06323204B1
公开(公告)日：2001-11-27
申请号：US09222844
申请日：1998-12-30
申请人： James A. Burke , Michael E. Garst , Larry A. Wheeler
发明人： James A. Burke , Michael E. Garst , Larry A. Wheeler
IPC分类号： A61K31495
CPC分类号： A61K31/495 , A61K31/498
摘要： A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R1 and R2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R3, R4 and R5 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.
摘要翻译：治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供所需治疗效果，所述化合物选自具有下式的那些化合物：及其药学上可接受的酸加成盐及其混合物，其中R 1 并且R 2各自选自含有1至4个碳原子的烷基和含有1至4个碳原子的烷氧基，2-咪唑啉-2-基氨基可以在5-，6-，7- - 或8-位的喹喔啉核，R3，R4和R5各自位于喹喔啉核的剩余的5-，6-，7-或8-位之一，并且独立地选自Cl ，Br，H和含有1至3个碳原子的烷基。当向哺乳动物施用时，这些化合物提供期望的治疗效果，例如减少外周疼痛。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式